Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Prevention Science
Published in: Prevention Science 2/2010

01-06-2010

An Extended Model of Reasoned Action to Understand the Influence of Individual- and Network-Level Factors on African Americans’ Participation in HIV Vaccine Research

Authors: Paula M. Frew, Matthew Archibald, Dazon Dixon Diallo, Su-I Hou, Takeia Horton, Kayshin Chan, Mark J. Mulligan, Carlos del Rio

Published in: Prevention Science | Issue 2/2010

Login to get access

Abstract

In the United States, the number and proportion of HIV/AIDS cases among black/African Americans continue to highlight the need for new biomedical prevention interventions, including an HIV vaccine, microbicide, or new antiretroviral (ARV) prevention strategies such as pre-exposure prophylaxis (PrEP) to complement existing condom usage, harm reduction methods, and behavioral change strategies to stem the HIV epidemic. Although black/African Americans are disproportionately impacted by HIV/AIDS, their participation in HIV clinical research continues to have unique challenges. We theorize that interaction among multilevel factors creates ideal alignment for minority participation in HIV clinical studies. Thus, we initially set out to test an extended model of reasoned action with 362 participants to understand the interplay of sociopsychological and network-level considerations influencing minority participation in HIV prevention research efforts. In this study, we linked the intrapersonal dimensions of attitudes, beliefs, and normative concerns to community-level components, appraisal of involvement with the clinical research organization, an entity which operates within a networked structure of community partner agencies, and identification with coalition advocacy aims. Various participatory outcomes were explored including involvement in future HIV vaccine community functions, participation in community promotion of HIV vaccine research, and community mobilization. Three-stage least squares estimates indicated similar findings across three models. Significant effects demonstrate the importance of positive attitudes toward HIV vaccine research, favorable health research beliefs, perceived social support for participation, HIV/AIDS issue engagement, and perceived relevance of the clinical research site’s mission and values. Identification of these nuanced pathway effects provides implications for tailored community program development.
Literature
AIDS Vaccine Advocacy Coalition. (2008). Anticipating the results of PrEP trials: A powerful new HIV prevention tool may be on the horizon. Are we prepared? Retrieved September 24, 2008, from http://​www.​avac.​org/​prep08.​pdf.
Ajzen, I. (1991). The theory of planned behavior. Organizational Behavior and Human Decision Processes, 50, 179–211.CrossRef
Ajzen, I., & Fishbein, M. (1980). Understanding attitudes and predicting behavior. Englewood Cliffs, NJ: Prentice-Hall.
Ajzen, I., & Madden, T. J. (1986). Prediction of goal-directed behavior: Attitudes, intentions, and perceived behavioral control. Journal of Experimental Social Psychology, 22, 453–474.CrossRef
Albarracin, D., & Wyers, R. S. (2000). The cognitive impact of past behavior: Influences on beliefs, attitudes, and future behavioral decisions. Journal of Personality and Social Psychology, 79, 5–22.CrossRefPubMed
Albarracin, D., Johnson, B. T., Fishbein, M., & Meullerleile, P. A. (2001). Theories of reasoned action and planned behavior as models of condom use: A meta-analysis. Psychological Bulletin, 127, 142–161.CrossRefPubMed
Allen, M., Liang, T., Salvia, T., Tjugum, B., Gulakowski, R., & Murguia, M. (2005). Assessing the attitudes, knowledge, and awareness of HIV vaccine research among adults in the United States. Journal of Acquired Immune Deficiency Syndrome, 40, 617–624.CrossRef
Bagozzi, R. P., Lee, K., & Van Loo, M. F. (2001). Decisions to donate bone marrow: The role of attitudes and subjective norms across cultures. Psychology & Health, 16, 29–56.CrossRef
BeLue, R., Taylor-Richardson, K. D., Lin, J., Rivera, A. T., & Grandison, D. (2006). African Americans and participation in clinical trials: Differences in beliefs and attitudes by gender. Contemporary Clinical Trials, 27, 498–505.CrossRefPubMed
Berkley, S. F., & Koff, W. C. (2007). Scientific and policy challenges to development of an AIDS vaccine. The Lancet, 370, 94–101.CrossRef
Bollen, K. A. (1996). An alternative two stage least squares (2SLS) estimator for latent variable equations. Psychometrika, 61, 109–121.CrossRef
Bollen, K. A. (2001). Two-stage least squares and latent variable models: Simultaneous estimation and robustness to misspecifications. In R. Cudeck, S. D. Toit, & D. Sorbom (Eds.), Structural equation modeling: Present and future. A Festschrift in Honor of Karl Joreskog (pp. 119–138). Lincoln, NC: Scientific Software.
Brown, T. A. (2006). Confirmatory factor analysis for applied research (1st ed.). New York: Guilford.
Brown-Peterside, P., Chiasson, M. A., Ren, L., & Koblin, B. A. (2000). Involving women in HIV vaccine efficacy trials: Lessons learned from a vaccine preparedness study in New York City. Journal of Urban Health, 77, 425–437.CrossRefPubMed
Cargill, V. A., & Stone, V. E. (2005). HIV/AIDS: A minority health issue. Medical Clinics of North America, 89, 895–912.CrossRefPubMed
Centers for Disease Control and Prevention. (2007a). HIV/AIDS surveillance report. Rev ed (Vol. 17, pp. 1–54). Atlanta, GA: US Department of Health and Human Services.
Centers for Disease Control and Prevention. (2007b). Rapid HIV testing in outreach and other community settings—United States, 2004–2006. Morbidity and Mortality Weekly, 56, 1233–1237.
Corbie-Smith, G., Thomas, S. B., Williams, M. V., & Moody-Ayers, S. (1999). Attitudes and beliefs of African Americans toward participation in medical research. Journal of General Internal Medicine, 14, 537–546.CrossRefPubMed
Crosby, R. A., Holtgrave, D. R., Bryant, L., & Frew, P. M. (2004a). Correlates of negative intent to receive an AIDS vaccine: An exploratory study. International Journal of STDs & AIDS, 14, 552–557.CrossRef
Crosby, R. A., Holtgrave, D. R., Bryant, L., & Frew, P. M. (2004b). Factors associated with the acceptance of an AIDS vaccine: An exploratory study. Preventive Medicine, 39, 804–808.CrossRefPubMed
Curbow, B., Fogarty, L. A., McDonnell, K. A., Chill, J., & Scott, L. B. (2006). The role of physician characteristics in clinical trial acceptance: Testing pathways of influence. Journal of Health Communication, 11, 199–218.CrossRefPubMed
Davis, C., & Randhawa, G. (2006). The influence of religion on organ donation and transplantation among the Black Caribbean and Black African population—a pilot study in the United Kingdom. Ethnicity & Disease, 16, 281–285.
Djomand, G., Katzman, J., di Tommaso, D., Hudgens, M., Counts, G., Koblin, B., et al. (2005). Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. Public Health Reports, 120, 543–548.PubMed
Fauci, A., Johnston, M., Dieffenbach, C., Burton, D., Hammer, S., Hoxie, J., et al. (2008). HIV vaccine research: The way forward. Science, 321, 530–532.CrossRefPubMed
Fishbein, M., & Ajzen, I. (1975). Belief, attitude, intention, and behavior. Menlo Park, CA: Addison-Wesley.
Frew, P. M., Archibald, M., Martinez, N., del Rio, C., & Mulligan, M. (2008a). Promoting HIV vaccine research in the African American community: Does the theory of reasoned action explain potential outcomes of involvement? Challenge: The Journal of the Morehouse Research Institute, 13, 61–97.
Frew, P. M., Crosby, R. A., Salazar, L. F., Gallinot, L., Bryant, L. O., & Holtgrave, D. R. (2008b). Acceptance of an HIV/AIDS vaccine among minority women. Journal of the National Medical Association, 100, 802–813.
Frew, P. M., del Rio, C., Clifton, S., Archibald, M., Hormes, J., & Mulligan, M. J. (2008c). Factors influencing HIV vaccine community engagement in the urban South. Journal of Community Health, 33, 259–269.CrossRef
Fuchs, J., Durham, M., McLellan-Lemal, E., Vittinghoff, E., Colfax, G., Gurwith, M., et al. (2007). Negative social impacts among volunteers in an HIV vaccine efficacy trial. Journal of Acquired Immune Deficiency Syndromes, 47, 1–7.
Gagnon, M. P., & Godin, G. (2000). Young adults and HIV vaccine: Determinants of intention of getting immunized. Canadian Journal of Public Health, 91, 432–434.
Gifford, A. L., Cunningham, W. E., Heslin, K. C., Andersen, R. M., Nakazono, T., Lieu, D. K., et al. (2002). Participation in research and access to experimental treatments by HIV-infected patients. New England Journal of Medicine, 346, 1373–1402.CrossRefPubMed
Giocos, G., Kagee, A., & Swartz, L. (2007). Predicting hypothetical willingness to participate (WTP) in a future phase III HIV vaccine trial among high-risk adolescents. AIDS and Behavior, 11, 842–851.CrossRef
Halpern, S. D., Metzger, D. S., Berlin, J. A., & Ubel, P. A. (2001). Who will enroll? Predicting participation in a phase II AIDS vaccine trial. Journal of Acquired Immune Deficiency Syndromes, 27, 281–288.PubMed
Kkafaar, Z., Kagee, A., Lesch, A., & Swartz, L. (2007). Is participation in HIV vaccine trials a health promoting behaviour? AIDS Care, 19, 1307–1309.CrossRef
Kline, R. B. (2005). Principles and practice of structural equation modeling (2nd ed.). New York: Guilford.
Koblin, B., Holte, S., Lenderking, B., & Heagerty, P. (2000). Readiness for HIV vaccine trials: Changes in willingness and knowledge among high-risk populations in the HIV network for prevention trials. Journal of Acquired Immune Deficiency Syndromes, 24, 451–457.PubMed
Koniak-Griffin, D., & Stein, J. A. (2006). Predictors of sexual risk behaviors among adolescent mothers in a human immunodeficiency virus prevention program. Journal of Adolescent Health, 38, 297. (e.291–211).PubMed
Landovitz, R. (2007). Recent efforts in biomedical prevention of HIV. Topics in HIV Medicine, 15, 99–103.PubMed
Leventhal, H., Brissette, I., & Leventhal, E. A. (2003). The common-sense model of self-regulation of health and illness. In L. D. Cameron & H. Leventhal (Eds.), The self-regulation of health and illness behaviour (pp. 42–65). London, UK: Routledge.
Liu, A. Y., Grant, R. M., & Buchbinder, S. P. (2006). Preexposure prophylaxis for HIV: Unproven promise and potential pitfalls. Journal of the American Medical Association, 296, 863–865.CrossRefPubMed
McCormack, S., Hayes, R., Lacey, C. J. N., & Johnson, A. M. (2001). Science, medicine, and the future: Microbicides in HIV prevention. British Medical Journal, 322, 410–413.CrossRefPubMed
McKnight, P. E., McKnight, K. M., Sidani, S., & Figueredo, A. J. (2007). Missing data: A gentle introduction. New York: Guilford.
Mclaws, M. L., Irwig, L. M., Oldenburg, B., Mock, P., & Ross, M. W. (1996). Predicting intentions to use condoms in homosexual men: An application and extension of the theory of reasoned action. Psychology & Health, 11, 745–755.CrossRef
Meyers, L. S., Gamst, G., & Guarino, A. J. (2006). Applied multivariate research: Design and interpretation. Thousand Oaks, CA: Sage.
Miedema, F. (2008). A brief history of HIV vaccine research: Stepping back to the drawing board? AIDS, 22, 1699–1703.CrossRefPubMed
Moore, J., Klasse, P., Dolan, M., & Ahuja, S. (2008). AIDS/HIV. A STEP into darkness or light? Science, 320, 753–755.CrossRefPubMed
Morrow, G., Hickok, J., & Burish, T. (1994). Behavioral aspects of clinical trials. An integrated framework from behavior theory. Cancer, 74, 2676–2682.CrossRefPubMed
Muhib, F., Lin, L., Stueve, A., Miller, R., Ford, W., Johnson, W., et al. (2001). A venue-based method for sampling hard-to-reach populations. Public Health Reports, 116, 216–222.CrossRefPubMed
National Medical Association. (2001). Recommendation of the clinical trials consensus panel. Journal of the National Medical Association, 92, 464–471.
Newman, P. A. (2006). Toward a science of community engagement. The Lancet, 367, 302.CrossRef
Newman, P. A., Duan, N., Lee, S. J., Rudy, E. T., Seiden, D. S., Kakinami, L., et al. (2005). HIV vaccine acceptability among communities at risk: The impact of vaccine characteristics. Vaccine, 24, 2094–2101.CrossRefPubMed
Newman, P. A., Duan, N., Roberts, K. J., Seiden, D. S., Rudy, E. T., Swendeman, D., et al. (2006). HIV vaccine trial participation among ethnic minority communities. Journal of Acquired Immune Deficiency Syndromes, 41, 210–217.CrossRefPubMed
Peterson, J. L., Coates, T. J., Catania, J. A., Middleton, L., Hilliard, B., & Hearst, N. (1992). High-risk sexual behavior and condom use among gay and bisexual African-American men. American Journal of Public Health, 82, 1490–1494.CrossRefPubMed
Porter, J. P., Glass, M. J., & Koff, W. C. (1989). Ethical considerations in AIDS vaccine testing. Review of Human Subjects Research, 11, 1–4.PubMed
Potts, M. (1994). The urgent need for a vaginal microbicide in the prevention of HIV transmission. American Journal of Public Health, 84, 890–891.CrossRefPubMed
Prejean, J., Song, R., An, Q., & Hall, H. (2008). Subpopulation estimates from the HIV incidence surveillance system—United States, 2006. Morbidity and Mortality Weekly, 57, 985–989.
Priddy, F. H., Cheng, A. C., Salazar, L. F., & Frew, P. M. (2006). Racial and ethnic differences in knowledge and willingness to participate in HIV vaccine trials in an urban population in the Southeastern US. International Journal of STDs & AIDS, 17, 99–102.CrossRef
Quinn, S. C. (2004). Ethics in public health research: Protecting human subjects: The role of community advisory boards. American Journal of Public Health, 94, 918–922.CrossRefPubMed
Reeder, G. D., Davison, D. M., Gipson, K. I., & Hesson-McInnis, M. S. (2001). Identifying the motivations of African American volunteers working to prevent HIV/AIDS. AIDS Education and Prevention, 13, 343–354.CrossRefPubMed
Roberts, K. J., Newman, P. A., Duan, N., & Rudy, E. T. (2005). HIV vaccine knowledge and beliefs among communities at elevated risk: Conspiracies, questions and confusion. Journal of the National Medical Association, 97, 1662–1671.PubMed
Rossi, L. (2008). HIV prevention researchers to compare common ARV as a pill and vaginal gel in unique study: Getting inside the cells and minds of women: Trial looks at drug absorption and adherence of different formulations of tenofovir. Retrieved July 17, 2008, from http://​www.​mtnstopshiv.​org/​node/​462.
Roth, P. L. (1994). Missing data—a conceptual review for applied psychologists. Personnel Psychology, 47, 537–560.CrossRef
Salazar, L. F., Holtgrave, D. R., Crosby, R. A., Frew, P. M., & Peterson, J. L. (2005). Issues related to gay and bisexual men’s acceptance of a future AIDS vaccine. International Journal of STDs & AIDS, 16, 546–548.CrossRef
Sanders, S. A., Graham, C. A., Yarber, W. L., Crosby, R. A., Dodge, B., & Milhausen, R. R. (2006). Women who put condoms on male partners: Correlates of condom application. American Journal of Health Behavior, 30, 460–466.PubMed
Sheeran, P. (2002). Intention-behavior relations: A conceptual and empirical review. In W. Stroebe & M. Hewstone (Eds.), European review of social psychology (Vol. 12, pp. 1–36). Chichester, UK: Wiley.CrossRef
Smith, Y. R., Johnson, A. M., Newman, L. A., Greene, A., Johnson, T. R. B., & Rogers, J. L. (2007). Perceptions of clinical research participation among African American women. Journal of Women’s Health, 16, 423–505.CrossRefPubMed
Sneed, C. D., & Morisky, D. E. (1998). Applying the theory of reasoned action to condom use among sex workers. Social Behavior and Personality, 26, 317–327.CrossRefPubMed
Strauss, R., Sengupta, S., Kegeles, S., McLellan, E., Metzger, D., & Eyre, S. (2001). Willingness to volunteer in future preventive HIV vaccine trials: Issues and perspectives from three US communities. Journal of Acquired Immune Deficiency Syndromes, 26, 63–71.PubMed
Traylor, M. B., & Joseph, W. B. (1984). Measuring consumer involvement with products: Developing a general scale. Psychology & Marketing, 1, 65–77.CrossRef
UNAIDS, & AIDS Vaccine Advocacy Coalition. (2007). Good participatory practice: Guidelines for biomedical HIV prevention trials. Geneva, Switzerland.
Weiss, H. A., Halperin, D., Bailey, R. C., Hayes, R. J., Schmid, G., & Hankins, C. A. (2008). Male circumcision for HIV prevention: From evidence to action? AIDS, 22, 567–574.CrossRefPubMed
Youle, M., & Wainberg, M. A. (2003). Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. Journal of the International Associated Physicians in AIDS Care, 2, 102–105.CrossRef
Zaichkowsky, J. L. (1985). Measuring the involvement construct. Journal of Consumer Research, 12, 341–352.CrossRef
Metadata
Title
An Extended Model of Reasoned Action to Understand the Influence of Individual- and Network-Level Factors on African Americans’ Participation in HIV Vaccine Research
Authors
Paula M. Frew
Matthew Archibald
Dazon Dixon Diallo
Su-I Hou
Takeia Horton
Kayshin Chan
Mark J. Mulligan
Carlos del Rio
Publication date
01-06-2010
Publisher
Springer US
Published in
Prevention Science / Issue 2/2010
Print ISSN: 1389-4986
Electronic ISSN: 1573-6695
DOI
https://doi.org/10.1007/s11121-009-0162-9

Other articles of this Issue 2/2010

Prevention Science 2/2010 Go to the issue

OriginalPaper

LateNight Penn State Alcohol-Free Programming: Students Drink Less on Days They Participate

OriginalPaper

Concurrent Alcohol Use or Heavier Use of Alcohol and Cigarette Smoking Among Women of Childbearing Age with Accessible Health Care

ReviewPaper

When Early Crime Prevention Goes to Scale: A New Look at the Evidence

OriginalPaper

An Experimental Evaluation of the All Stars Prevention Curriculum in a Community After School Setting

OriginalPaper

Hepatitis Vaccination of Men Who Have Sex with Men at Gay Pride Events

OriginalPaper

The Relative Importance of Provider, Program, School, and Community Predictors of the Implementation Quality of School-Based Prevention Programs